Valeriana officinalis is a medicinal herb which produces a suite of compounds in its root tissue useful for 9 treatment of anxiety and insomnia. The sesquiterpene components of the root extract, valerenic acid and 1 0 valerena-1,10-diene, are thought to contribute to most of the observed anxiolytic of Valerian root 1 1 preparations. However, valerenic acid and its biosynthetic intermediates are only produced in low 1 2 quantities in the roots of V. officinalis. Thus, in this report, Escherichia coli was metabolically engineered 1 3
Introduction 2 9
Valeriana officinalis is a medicinal wild herb indigenous to many habitats, and the root of this 3 0 plant is used as a nutraceutical preparation (Valerian) that is currently used for the treatment of anxiety Bacterial strains and growth conditions 9 9 E. coli JM109 (New England Biolabs) was used as the host for all routine cloning manipulations, 1 0 0 and E. coli DH5αZ1 (Expressys, Germany) and E. coli BL21(DE3) (ThermoFisher) were used as hosts for 1 0 1 sesquiterpene production ( Supplementary Table 1 ). E. coli DH5αZ1 overexpresses a copy of the lacIq 1 0 2 repressor on the chromosome for efficient repression of the lac operator (Lutz and Bujard, 1997) .
0 3
Chemically competent E. coli were generated with the E. coli Mix and Go Transformation Kit (ZYMO 1 0 4
Research) and were transformed using standard molecular methodologies (Sambrook and W Russell, 1 0 5 2001). E. coli strains were grown in LB agar or LB broth at 37 C for routine maintenance. For 1 0 6 production of sesquiterpenes, E. coli DH5αZ1 derivatives were grown in 2xYT with supplemented glycerol 1 0 7 at 30 C. for production of valerenadiene. For expression of the mevalonic acid pathway, bacterial 1 0 8 growth media was buffered with phosphate buffered saline using a stock solution of 10x PBS (Sambrook 1 0 9 and W Russell, 2001) . Strains were supplemented with ampicillin (100 µg mL -1 ), chloramphenicol (35 µg 1 1 0 mL -1 ), and kanamycin (50 µg mL -1 ) as necessary. When multiple plasmids were co-expressed, the 1 1 1 chloramphenicol and kanamycin concentrations were adjusted to one-half these amounts.
2
Cloning of vds and engineered MEP pathway constructs 1 1 3
Oligonucleotide primers were synthesized by IDT-DNA ( Supplementary Table 2 ), and sequences 1 1 4 were verified by sequencing analysis (ACGT, Inc.). Polymerase chain reaction was carried out using 1 1 5
Primestar® HS Polymerase (Takara Bio.) by following the manufacturer's protocols. The wildtype 1 1 6 valerenadiene synthase gene (wvds) gene was amplified via polymerase chain reaction from the 1 1 7 pET28a(+)-VoTPS1 (hereafter referred to as pET-wvds) construct as described previously (Yeo et al., 1 1 8 2013). The cvds gene was codon-optimized for expression in E. coli, synthesized, and spliced into 1 1 9 cloning vector pUC57-cvds (GenScript). The cvds gene was amplified via polymerase chain reaction, and 1 2 0 both the wvds and cvds genes were cut and spliced into the EcoRI/BamHI restriction sites of pZE12MCS 1 2 1 pBbA5c-MevT(CO)-MBIS(CO, ispA) was a gift from Jay Keasling & Taek Soon Lee (Addgene 1 3 4 plasmid # 35151). For co-expression of valerenadiene synthase and the mevalonate pathway, E. coli 1 3 5 competent cells were co-transformed with the relevant constructs and plated on LB agar supplemented 1 3 6 with antibiotics. For terminal endpoint assays, E. coli strains were grown in 1 mL of LB supplemented 1 3 7 with antibiotics for 12-16 hours until the strains were in stationary phase growth, and then they were 1 3 8 inoculated into 5 mL 2x YT medium containing 3% glycerol with an overlay of 1 mL of decane. For time 1 3 9 course assays, E. coli strains were grown in 50 mL 2x YT medium containing 3% glycerol with an overlay 1 4 0 of 10 mL of decane. Time points were collected at 12, 24, 36, 48, 72, and 96 To evaluate the production of valerenadiene synthase in E. coli, the gene encoding wildtype 1 6 0 valerenadiene synthase (wvds) from V. officinalis was cloned under the control of the IPTG-inducible 1 6 1 P LlacO1 promoter of high copy number expression plasmid pZE12MCS to afford pZE-wVDS. Previously, 1 6 2 other groups have reported that sesquiterpene production in E. coli is limited by poor expression of 1 6 3 cognate plant terpene synthases (Martin et al., 2001; Wang et al., 2011) . We surmised that the wvds 1 6 4 gene may encode several rare codons that inhibit optimal translation in E. coli. Therefore, we 1 6 5 synthesized a codon-optimized version of the valerenadiene synthase gene for expression in E. coli 1 6 6 (GenScript) and fused it to the P LlacO1 to afford pZE-cVDS. pZE-wVDS, pZE-cVDS, and empty 1 6 7 pZE12MCS vector were transformed in E. coli. The E. coli lines were grown in 5 mL of LB medium 1 6 8 6 overlaid with decane for 48 hours and induced with IPTG. A major valerenadiene peak was detected in 1 6 9 extracts of pZE-wVDS and pZE-cVDS cultures that eluted at the same retention time and exhibited 1 7 0 identical mass fragmentation pattern to valerenadiene standard ( Supplementary Figure 1 ). This peak was 1 7 1 not detected in pZE12MCS control strains, which confirmed low production of valerenadiene in the VDS- (Figure 2 ). This results suggests that the codon-optimized valerenadiene synthase is more 1 7 5 efficiently expressed than the wildtype version, which results in a 3-fold improvement in valerenadiene 1 7 6 titer.
7 7
However, the yields of valerenadiene achieved were quite low, and we surmised this was likely 1 7 8 due to low levels of prenyl phosphate precursors (IPP, DMAPP, and FPP). The endogenous MEP 1 7 9 pathway of E. coli produces a small pool of FPP that is the precursor for trans-octaprenyl diphosphate 1 8 0 (ODP) in production of ubiquinone and cis, trans-undecaprenyl diphosphate (UDP) for production of and co-workers engineered higher levels of C 20 abietadiene production and increased biomass when 2 0 4 glycerol supplemented media was used (e.g. increasing abietadiene specific productivity from 1 2 0 5 mg/L/OD 600 without glycerol supplementation to 2.5 mg/L/OD 600 with glycerol supplementation) (Morrone 2 0 6 et al., 2010). E. coli pZE-wVDS/pSTV-dxs-idi-fps and E. coli pZE-cVDS/pSTV-dxs-idi-fps were grown in 5 2 0 7 mL of 2x YT medium supplemented with 0 to 5% glycerol. The E. coli pZE-wVDS/pSTV-dxs-idi-fps 2 0 8 valerenadiene production increased 15-fold from 0.11 mg/L to 1.5 mg/L when supplemented with glycerol, 2 0 9 however, further production was possibly stymied by poor heterologous expression of valerenadiene 2 1 0 synthase. In contrast, E. coli pZE-cVDS/pSTV-dxs-idi-fps demonstrated better responsiveness to the 2 1 1 glycerol supplementation, as valerenadiene productivity increased from 5.1 mg/L to 11.0 mg/L when 2 1 2 supplemented with 3% glycerol (Figure 3 ). Therefore, 3% glycerol was used for all further experiments. 
1
Engineering of vds under the P trc promoter 2 2 2 We hypothesized that low-level expression of the terpene synthase from the P LlacO1 promoter 2 2 3 might be a metabolic rate-limiting factor in the turnover of FPP substrate. Based on the previous 2 2 4 experiment, expression of the cvds gene resulted in 5-10-fold higher quantities of valerenadiene than 2 2 5 expression of wvds, depending on glycerol supplementation, which was inferred to be the direct result of 2 2 6 higher concentration of terpene synthase catalyst in the E. coli cell. Therefore, the cvds gene was fused 2 2 7 to the strong P trc promoter to afford construct pTrcHis-cvds. This construct was expressed alone and co-2 2 8 expressed with pSTV-dxs-idi-fps in E. coli DH5αZ1 cells in triplicate 5 mL 2xYT+3% glycerol 2 2 9 fermentations for 48 hours. The strain harboring pTrcHis-cvds produced 0.046 mg/L valerenadiene, 2 3 0 whereas the strain harboring pTrcHis-cvds and pSTV-dxs-idi-fps produced approximately 20.3 mg/L 2 3 1 ( Supplementary Figure 2) . This represents a 440-fold improvement over the pTrcHis-cvds only 2 3 2 expression line. Furthermore, expression of the cvds gene by the P trc promoter (e.g. by strain E. coli 2 3 3 DH5αZ1/(pTrcHis-cvds)/(pSTV-dxs-idi-fps)) represented a 40% increase in valerenadiene titers as 2 3 4 compared to expression from P LlacO1 (e.g. by strain E. coli DHαZ1/(pZE-cvds)/(pSTV-dxs-idi-fps)).
3 5
Recently, the MEP pathway has been demonstrated to be subject to endogenous regulation by E.
3 6
coli, possibly due to feedback inhibition of the metabolite methylerythritol cyclodiphosphate (MEcDP) 2 3 7 (Banerjee and Sharkey, 2014). We rationalized that FPP enhancement might be limited via the MEP 2 3 8 pathway, therefore we co-expressed an exogenous MVA pathway to greatly augment FPP precursor 9 levels along with pTrcHis-cvds. In a previous study, Peralta-Yahya and co-workers engineered a Table 1 ). The three upstream gene products (atoB, hmgs, thmgr) 2 4 5 convert acetyl-CoA to mevalonic acid, and the five downstream gene products (erg12, erg8, mvd1, idi, 2 4 6 ispA) convert mevalonic acid to farnesyl pyrophosphate (Figure 1) . Similarly, E. coli DH5αZ1 was 2 4 7 transformed with pTrcHis-cvds and pBbA5c-MevT(CO)-MBIS(CO, ispA) and grown in triplicate 5 mL 2 4 8 2xYT+3% glycerol fermentations for 48 hours. This strain produced 42.5 mg/L valerenadiene, a 1000-fold 2 4 9 increase over the cvds-expressing line and a 2-fold increase over the engineered MEP pathway 2 5 0 ( Supplementary Figure 2) . This result demonstrated that the mevalonic acid pathway efficiently coupled 2 5 1 the microbial synthesis of FPP to valerenadiene synthase to produce significant levels of valerenadiene.
5 2
Thus, the mevalonic acid pathway was used for further experiments. These results were further confirmed 2 5 3 in a time course experiment of the same strain, which achieved a titer of 35 mg/L valerenadiene at 24 2 5 4 hours ( Figure 5 ).
5 5
Co-expression of vds with the T7 RNA polymerase promoter and MVA pathway 2 5 6
We observed that the P trc -cvds gene constructs demonstrated more robust production of 2 5 7 valerenadiene than the comparatively weaker P LacO1 -cvds gene constructs, and we inferred that levels of 2 5 8 VDS catalyst may be rate-limiting in this latter system. Therefore, we decided to compare the expression 
1 5
However, the greatest increases in valerenadiene yield involved heterologous expression of the 3 1 6
Saccharomyces cerevisiae mevalonic acid pathway. Expression of the MVA pathway resulted in an 3 1 7 unregulated metabolic flux towards FPP, which could be efficiently coupled to valerenadiene synthase for 3 1 8 production of 62.0 mg/L valerenadiene in culture tubes with a specific productivity of 19.4 mg/L/OD 600 .
1 9
This study showed that E. coli is capable of high-level production of valerenadiene with relatively minimal 3 2 0 optimization of the production media and commercially available expression vectors, such as pBBa5c-
2 1
MevT-MBIS(CO,IspA). Further efforts to improve valerenadiene yield will require optimization of the 
